









市场行情
/
股票
/
nasdaq-vir
/

Vir Biotechnology Inc

VIR

6.110USD

+0.120+2.00%

收盘 12/24, 13:00（美东）报价延迟15分钟

849.43M总市值

亏损市盈率 TTM



Vir Biotechnology Inc

6.110

+0.120+2.00%

概览公司财务分析

概览

公司

财务

分析

关于 Vir Biotechnology Inc 公司

Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes infectious disease programs for chronic hepatitis delta and chronic hepatitis B infections and multiple dual-masked T-cell engagers across validated targets in solid tumor indications. It also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Tobevibart is an investigational neutralizing monoclonal antibody (mAb) that has been engineered for immune engagement and targets a conserved region on the hepatitis B surface antigen (HBsAg). Elebsiran is an investigational HBV-targeted small interfering RNA (siRNA) that reduces HBsAg. Its pipeline includes VIR-5818, VIR-5500, VIR-5525, and HIV Cure. It also has rights to the PRO-XTEN masking platform for oncology and infectious disease.

Vir Biotechnology Inc简介



公司代码VIR

公司名称Vir Biotechnology Inc

上市日期Oct 11, 2019

CEODe Backer (Marianne)

员工数量408

证券类型Ordinary Share

年结日Oct 11

公司地址1800 Owens Street

城市SAN FRANCISCO

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编94158

电话14159064324

网址https://www.vir.bio/

公司代码VIR

上市日期Oct 11, 2019

CEODe Backer (Marianne)

Vir Biotechnology Inc公司高管



名称

名称/职务

职务

持股

持股变动

Mr. Robert J. (Bob) More

Independent Director

32.66K

-30.05%

Mr. Jeffrey S. (Jeff) Hatfield

Independent Director

23.81K

+50.61%

Dr. Marianne De Backer, Ph.D.

Chief Executive Officer, Director

19.03K

-80.53%

Ms. Saira Ramasastry

Independent Director

14.62K

+120.86%

Dr. Norbert W. Bischofberger, Ph.D.

Independent Director

8.00K

Ms. Vanina De Verneuil, J.D.

Executive Vice President, General Counsel, Corporate Secretary

936.00

-80.03%

Dr. Mark Eisner, M.D.

Executive Vice President, Chief Medical Officer

Ms. Janet Napolitano, J.D.

Independent Director

Mr. Jason V. O'byrne

Chief Financial Officer, Executive Vice President

Dr. Vicki L. Sato, Ph.D.

Independent Chairman of the Board

名称

名称/职务

职务

持股

持股变动

Mr. Robert J. (Bob) More

Independent Director

32.66K

-30.05%

Mr. Jeffrey S. (Jeff) Hatfield

Independent Director

23.81K

+50.61%

Dr. Marianne De Backer, Ph.D.

Chief Executive Officer, Director

19.03K

-80.53%

Ms. Saira Ramasastry

Independent Director

14.62K

+120.86%

Dr. Norbert W. Bischofberger, Ph.D.

Independent Director

8.00K

Ms. Vanina De Verneuil, J.D.

Executive Vice President, General Counsel, Corporate Secretary

936.00

-80.03%

收入明细

FY2024

由于公司未披露，未能获取相关数据

地区USD

名称

营收

占比

United States

74.20M

0.00%

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 11月16日周日

持股股东

股东类型

持股股东

占比

SB Investment Advisers (UK) Limited

10.26%

BlackRock Institutional Trust Company, N.A.

9.86%

ARCH Venture Partners

9.28%

The Vanguard Group, Inc.

9.18%

GSK plc

6.15%

其他

55.27%

持股股东

占比

SB Investment Advisers (UK) Limited

10.26%

BlackRock Institutional Trust Company, N.A.

9.86%

ARCH Venture Partners

9.28%

The Vanguard Group, Inc.

9.18%

GSK plc

6.15%

其他

55.27%

股东类型

持股股东

占比

Investment Advisor

29.37%

Investment Advisor/Hedge Fund

15.11%

Private Equity

11.97%

Venture Capital

9.75%

Corporation

6.15%

Hedge Fund

6.07%

Individual Investor

4.27%

Research Firm

3.10%

Foundation

1.12%

其他

13.09%

机构持股



更新时间: 10月1日周三

报告期

机构数

持股数

持股占比

持股变动

2025Q3

481

113.05M

81.28%

-6.82M

2025Q2

530

124.85M

89.88%

-15.28M

2025Q1

571

125.80M

91.30%

-16.44M

2024Q4

568

122.14M

89.06%

-13.83M

2024Q3

554

118.76M

86.83%

-17.44M

2024Q2

572

119.53M

87.47%

-20.55M

2024Q1

564

122.68M

91.07%

-16.10M

2023Q4

577

121.87M

90.75%

-16.40M

2023Q3

578

123.93M

92.29%

-3.81M

2023Q2

574

125.10M

93.31%

+332.42K

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

SB Investment Advisers (UK) Limited

16.68M

12.01%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

13.85M

9.97%

-523.21K

-3.64%

Jun 30, 2025

ARCH Venture Partners

12.92M

9.3%

Jun 30, 2025

The Vanguard Group, Inc.

13.20M

9.5%

+419.56K

+3.28%

Jun 30, 2025

GSK plc

8.55M

6.16%

Apr 01, 2025

State Street Investment Management (US)

5.25M

3.78%

-472.45K

-8.25%

Jun 30, 2025

Scangos (George A)

3.78M

2.72%

-550.77K

-12.72%

Apr 01, 2025

Dimensional Fund Advisors, L.P.

3.01M

2.17%

+323.54K

+12.05%

Jun 30, 2025

Fidelity Institutional Asset Management

2.60M

1.87%

+2.17M

+508.24%

Jun 30, 2025

OrbiMed Advisors, LLC

2.38M

1.71%

+132.47K

+5.89%

Jun 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

iShares Genomics Immunology and Healthcare ETF

1.13%

Virtus LifeSci Biotech Clinical Trials ETF

0.77%

Invesco NASDAQ Future Gen 200 ETF

0.65%

Global X Genomics & Biotechnology ETF

0.59%

Invesco S&P SmallCap Health Care ETF

0.34%

ALPS Medical Breakthroughs ETF

0.34%

Hypatia Women CEO ETF

0.27%

State Street SPDR S&P Biotech ETF

0.2%

ProShares Ultra Nasdaq Biotechnology

0.11%

Direxion Daily S&P Biotech Bull 3X Shares

0.1%

iShares Genomics Immunology and Healthcare ETF

占比1.13%

Virtus LifeSci Biotech Clinical Trials ETF

占比0.77%

Invesco NASDAQ Future Gen 200 ETF

占比0.65%

Global X Genomics & Biotechnology ETF

占比0.59%

Invesco S&P SmallCap Health Care ETF

占比0.34%

ALPS Medical Breakthroughs ETF

占比0.34%

Hypatia Women CEO ETF

占比0.27%

State Street SPDR S&P Biotech ETF

占比0.2%

ProShares Ultra Nasdaq Biotechnology

占比0.11%

Direxion Daily S&P Biotech Bull 3X Shares

占比0.1%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

常见问题

Vir Biotechnology Inc的前五大股东是谁？



Vir Biotechnology Inc 的前五大股东如下：
SB Investment Advisers (UK) Limited持有股份：16.68M，占总股份比例：12.01%。
BlackRock Institutional Trust Company, N.A.持有股份：13.85M，占总股份比例：9.97%。
ARCH Venture Partners持有股份：12.92M，占总股份比例：9.30%。
The Vanguard Group, Inc.持有股份：13.20M，占总股份比例：9.50%。
GSK plc持有股份：8.55M，占总股份比例：6.16%。